|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
22
|
|
pubmed:dateCreated |
2009-11-13
|
|
pubmed:abstractText |
Resistance to anti-HER2 monoclonal antibody trastuzumab is a relevant issue in breast cancer patients. Among the mechanisms implicated in trastuzumab resistance, increasing evidence supports a role of tumor microenvironment. We previously found that a novel toll-like receptor 9 agonist, referred to as immune modulatory oligonucleotide (IMO) and currently under clinical investigation, acts through epidermal growth factor receptor (EGFR) and shows direct antiangiogenic effects by cooperating with anti-EGFR or anti-VEGF drugs, thus interfering with cancer cells and microenvironment.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Angiogenesis Inhibitors,
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal,
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal, Humanized,
http://linkedlifedata.com/resource/pubmed/chemical/Oligonucleotides,
http://linkedlifedata.com/resource/pubmed/chemical/Receptor, erbB-2,
http://linkedlifedata.com/resource/pubmed/chemical/Toll-Like Receptor 9,
http://linkedlifedata.com/resource/pubmed/chemical/trastuzumab
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Nov
|
|
pubmed:issn |
1078-0432
|
|
pubmed:author |
pubmed-author:AgrawalSudhirS,
pubmed-author:BiancoRobertoR,
pubmed-author:CaputoRosaR,
pubmed-author:DamianoVincenzoV,
pubmed-author:GarbiCorradoC,
pubmed-author:GarofaloSoniaS,
pubmed-author:GelardiTeresaT,
pubmed-author:KandimallaEkambar RER,
pubmed-author:MerolaGerardinaG,
pubmed-author:RacioppiLuigiL,
pubmed-author:RosaRobertaR,
pubmed-author:TortoraGiampaoloG
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
15
|
|
pubmed:volume |
15
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
6921-30
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:19903791-Angiogenesis Inhibitors,
pubmed-meshheading:19903791-Animals,
pubmed-meshheading:19903791-Antibodies, Monoclonal,
pubmed-meshheading:19903791-Antibodies, Monoclonal, Humanized,
pubmed-meshheading:19903791-Breast Neoplasms,
pubmed-meshheading:19903791-Drug Resistance, Neoplasm,
pubmed-meshheading:19903791-Endothelium, Vascular,
pubmed-meshheading:19903791-Female,
pubmed-meshheading:19903791-Humans,
pubmed-meshheading:19903791-Mice,
pubmed-meshheading:19903791-Mice, Inbred BALB C,
pubmed-meshheading:19903791-Middle Aged,
pubmed-meshheading:19903791-Neoplasm Metastasis,
pubmed-meshheading:19903791-Neoplasm Transplantation,
pubmed-meshheading:19903791-Oligonucleotides,
pubmed-meshheading:19903791-Receptor, erbB-2,
pubmed-meshheading:19903791-Toll-Like Receptor 9
|
|
pubmed:year |
2009
|
|
pubmed:articleTitle |
A novel toll-like receptor 9 agonist cooperates with trastuzumab in trastuzumab-resistant breast tumors through multiple mechanisms of action.
|
|
pubmed:affiliation |
Departments of Endocrinologia ed Oncologia Molecolare e Clinica, and Biologia e Patologia Cellulare e Molecolare L. Califano, Università di Napoli Federico II, Napoli, Italy.
|
|
pubmed:publicationType |
Journal Article
|
